Roche/Ipsen Plan 2010 Filing For Once-Weekly GLP-1 Analog
Phase III studies pitting once-weekly taspoglutide against Lilly's Byetta and Merck's Januvia commence in the second half.
Phase III studies pitting once-weekly taspoglutide against Lilly's Byetta and Merck's Januvia commence in the second half.